Jesduvroq Approved for Anemia of CKD in Patients on Dialysis
Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor.
Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor.
The table provided is a review of notable updates that occurred in January 2023 for investigational products in development.
Draft recommendations around the new policy center on ‘individual risk-based questions to reduce the risk of transfusion-transmitted HIV’
Enjaymo is an immunoglobulin G subclass 4 monoclonal antibody.
The sNDA is supported by data from the phase 2 PIONEER trial that evaluated the efficacy and safety of avapritinib in patients with indolent systemic mastocytosis.
Researchers sought to determine whether corticosteroids would be an effective treatment for patients with chemotherapy-induced thrombocytopenia.
Lumoxiti was approved by the FDA in September 2018 for the treatment of adults with relapsed or refractory hairy cell leukemia.
Those with middle-age serum sodium >142 mmol/L also have increased risk for developing chronic diseases, premature mortality
Lunsumio is a first-in-class CD20xCD3 T-cell engaging bispecific antibody that targets CD20 on the surface of B cells and CD3 on the surface of T cells.